Wang Qun, Jia Siyu, Wang Zihan, Chen Hui, Jiang Xinyi, Li Yan, Ji Peng
College of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, China.
Department of International Medicine, The Second Hospital of Dalian Medical University, Dalian, China.
Front Med (Lausanne). 2024 Sep 25;11:1418786. doi: 10.3389/fmed.2024.1418786. eCollection 2024.
Liver fibrosis is a group of diseases that seriously affect the health of the world's population. Despite significant progress in understanding the mechanisms of liver fibrogenesis, the technologies and drugs used to treat liver fibrosis have limited efficacy. As a revolutionary genetic tool, gene editing technology brings new hope for treating liver fibrosis. Combining nano-delivery systems with gene editing tools to achieve precise delivery and efficient expression of gene editing tools that can be used to treat liver fibrosis has become a rapidly developing field. This review provides a comprehensive overview of the principles and methods of gene editing technology and commonly used gene editing targets for liver fibrosis. We also discuss recent advances in common gene editing delivery vehicles and nano-delivery formulations in liver fibrosis research. Although gene editing technology has potential advantages in liver fibrosis, it still faces some challenges regarding delivery efficiency, specificity, and safety. Future studies need to address these issues further to explore the potential and application of liver fibrosis technologies in treating liver fibrosis.
肝纤维化是一组严重影响全球人口健康的疾病。尽管在理解肝纤维化发生机制方面取得了重大进展,但用于治疗肝纤维化的技术和药物疗效有限。作为一种革命性的基因工具,基因编辑技术为治疗肝纤维化带来了新希望。将纳米递送系统与基因编辑工具相结合,以实现可用于治疗肝纤维化的基因编辑工具的精确递送和高效表达,已成为一个快速发展的领域。本文综述了基因编辑技术的原理和方法以及肝纤维化常用的基因编辑靶点。我们还讨论了肝纤维化研究中常见基因编辑递送载体和纳米递送制剂的最新进展。尽管基因编辑技术在肝纤维化方面具有潜在优势,但在递送效率、特异性和安全性方面仍面临一些挑战。未来的研究需要进一步解决这些问题,以探索肝纤维化技术在治疗肝纤维化中的潜力和应用。